| Saturday, February 23, 2013 |
| 06:00:00 |
New Presentation |
|
| 06:00:00 |
New Presentation |
|
| 18:55:00 |
Valve Evening Symposium | TAVR EVENING SYMPOSIUM: STARTING A TAVR PROGRAM IN YOUR INSTITUTION |
Paul J. Corso, Augusto D. Pichard
|
| 19:00:00 |
Valve Evening Symposium | Dinner and Case Presentations |
Augusto D. Pichard, Ron Waksman
|
| 19:15:00 |
Valve Evening Symposium | Aortic Stenosis: The Evolution of our Understanding of Pathophysiology and Therapeutic Modalities |
Robert O. Bonow
|
| 19:30:00 |
Valve Evening Symposium | Discussion |
Joseph Bavaria, Augusto D. Pichard, E. Murat Tuzcu, Alec Vahanian, Ron Waksman, Robert O. Bonow
|
| 19:40:00 |
Valve Evening Symposium | The Heart Team: How Does it Work for TAVR? |
E. Murat Tuzcu
|
| 19:55:00 |
Valve Evening Symposium | Discussion |
Joseph Bavaria, Augusto D. Pichard, E. Murat Tuzcu, Alec Vahanian, Ron Waksman, Robert O. Bonow
|
| 20:05:00 |
Valve Evening Symposium | How to Tailor the Optimal Treatment Modality for the Patient with AS |
Joseph Bavaria
|
| 20:20:00 |
Valve Evening Symposium | Discussion |
Joseph Bavaria, Augusto D. Pichard, E. Murat Tuzcu, Alec Vahanian, Ron Waksman, Robert O. Bonow
|
| 20:30:00 |
Valve Evening Symposium | Case in the Box |
Augusto D. Pichard
|
| 20:45:00 |
Valve Evening Symposium | Discussion |
Joseph Bavaria, Augusto D. Pichard, E. Murat Tuzcu, Alec Vahanian, Ron Waksman, Robert O. Bonow
|
| 20:55:00 |
Valve Evening Symposium | TAVR: The European experience |
Alec Vahanian
|
| 21:10:00 |
Valve Evening Symposium | Discussion |
Joseph Bavaria, Augusto D. Pichard, E. Murat Tuzcu, Alec Vahanian, Ron Waksman, Robert O. Bonow
|
| 21:20:00 |
Valve Evening Symposium | Adjourn |
|
| Sunday, February 24, 2013 |
| 03:45:00 |
CTO Forum | The Status of Collagenase for the Treatment of CTO |
Bradley H. Strauss
|
| 06:00:00 |
New Presentation |
|
| 06:00:00 |
CTO Forum | Patient Selection for CTO Recanalization: What Are the Appropriate Criteria? |
Tarek Helmy
|
| 06:00:00 |
New Presentation |
|
| 06:00:00 |
CTO Forum | Complications of CTO PCI I: Ischemia - Predictors, Prevention and Management |
William L. Lombardi
|
| 06:00:00 |
CTO Forum | Step-by-Step Review of the Retrograde Approach: Making the Connection - Reverse CART and CART |
Craig A. Thompson
|
| 06:00:00 |
Valve & Structural Heart Revolution I | My Own Experience with Mitral Clips |
Michael J. Mack
|
| 06:30:00 |
Valve & Structural Heart Revolution I | Taped Case Demonstration: Mitral Clip Procedure |
|
| 06:50:00 |
Valve & Structural Heart Revolution I | Tips for a Successful Mitral Clip Procedure |
Saibal Kar
|
| 07:10:00 |
Valve & Structural Heart Revolution I | How Do I Treat Functional MR? The Surgeon’s Perspective |
Steven F. Bolling
|
| 07:20:00 |
Valve & Structural Heart Revolution I | Update on Maze Technique and Results |
|
| 07:30:00 |
Valve & Structural Heart Revolution I | Is Aortic Valve Repair Superior to Replacement? |
|
| 07:40:00 |
Valve & Structural Heart Revolution I | Panel Discussion: TBA |
Niv Ad, Steven F. Bolling, Saibal Kar, Michael J. Mack, Ted Feldman
|
| 07:45:00 |
CTO Forum | Introduction and Welcome to the CRT CTO Club: A New Beginning |
Richard R. Heuser, Craig A. Thompson
|
| 07:55:00 |
Valve & Structural Heart Revolution I | MITRAL VALVE REPAIR |
Niv Ad, Steven A. Goldstein
|
| 07:55:00 |
CTO Forum | CTO 101: SETTING THE STAGE |
Richard R. Heuser, Craig A. Thompson
|
| 07:55:00 |
ACS & AMI Management | ANTIPLATELET CONTROVERSY FOR ACS: HOW WILL THIS iMPACT OUR PRACTICE |
David J. Cohen, Ron Waksman, Stephen Wiviott
|
| 08:00:00 |
CTO Forum | Treating CTOs: Is There Enough Evidence-Based Data? Or do We Need Further Randomized Clinical Trials |
Gerald S. Werner
|
| 08:00:00 |
Valve & Structural Heart Revolution I | Functional Mitral Regurgitation: When to Repair – The Surgeon’s Perspective |
Steven F. Bolling
|
| 08:00:00 |
ACS & AMI Management | New Mechanisms and Pathogenesis of Acute Coronary Syndromes |
Renu Virmani
|
| 08:10:00 |
CTO Forum | Indication for CTO PCI: Clinical Rationale and Appropriateness |
J. Aaron Grantham
|
| 08:10:00 |
Valve & Structural Heart Revolution I | The Echocardiographic Subtleties and Hallmarks of Diagnosing Structural and Functional Mitral Regurgitation |
Steven A. Goldstein
|
| 08:10:00 |
ACS & AMI Management | Why the Third Generation Antiplatelet Agents Are Superior to First and Second Generation |
Paul A. Gurbel
|
| 08:20:00 |
ACS & AMI Management | What Is the Standard of Care for Antiplatelet Therapy in Europe? |
Michael Joner
|
| 08:20:00 |
Valve & Structural Heart Revolution I | Current Surgical Standards for Mitral Leaflet and Chordal Repair |
Thierry Georges Mesana
|
| 08:30:00 |
ACS & AMI Management | What Is the Standard of Care for Antiplatelet Therapy in the US? |
Jeffrey S. Berger
|
| 08:30:00 |
Valve & Structural Heart Revolution I | Functional Mitral Regurgitation: When to Repair – The Interventional Cardiologist’s Perspective |
Ted Feldman
|
| 08:30:00 |
CTO Forum | Reduced Radiation Exposure During CTO PCI by a |
Gerald S. Werner
|
| 08:40:00 |
Valve & Structural Heart Revolution I | Pathology of the Mitral Valve: What You Need to Know |
Renu Virmani
|
| 08:40:00 |
ACS & AMI Management | Cost Analysis: Is it Still Cost Effective to Use Prasugrel or Ticagrelor vs. Generic Clopidogrel? |
David J. Cohen
|
| 08:40:00 |
CTO Forum | Wire Snaring, Externalization and More |
Patrick Whitlow
|
| 08:50:00 |
ACS & AMI Management | The Big Antiplatelet Debate: Why I Prefer Prasugrel Over Ticagrelor |
Stephen Wiviott
|
| 08:50:00 |
Valve & Structural Heart Revolution I | The Spectrum of Evolving Mitral Repair Techniques |
|
| 09:00:00 |
CTO Forum | How to Build Your Own CTO PCI Program |
Tarek Helmy
|
| 09:00:00 |
ACS & AMI Management | The Big Antiplatelet Debate: Why I Prefer Ticagrelor Over Prasugrel |
Paul A. Gurbel
|
| 09:00:00 |
Valve & Structural Heart Revolution I | Degenerative MR - The Surgical Landscape: Volumes, Techniques, and Early and Late Outcomes |
Michael J. Mack
|
| 09:10:00 |
ACS & AMI Management | Lessons from TRANSLATE-ACS |
Tracy Wang
|
| 09:10:00 |
Valve & Structural Heart Revolution I | MitraClip Results in Low and High Risk Degenerative MR: Emerging Data and Integrated Recommendations |
Peter C. Block
|
| 09:10:00 |
CTO Forum | Live Case Demonstration from Cannizzaro Hospital, Catania, Italy |
Alfredo R. Galassi, Barry D. Rutherford, Jacques J. Koolen
|
| 09:20:00 |
Valve & Structural Heart Revolution I | Percutaneous Approach to Mitral Valve Repair: Edge-to-Edge Mitral Leaflet Repair with the MitraClip--Technique Overview and a Taped Case |
Saibal Kar
|
| 09:20:00 |
ACS & AMI Management | How to Switch from Clopidogrel to Prasugrel or Ticagrelor |
|
| 09:30:00 |
ACS & AMI Management | Lessons from TRILOGY |
Stephen Wiviott
|
| 09:30:00 |
Valve & Structural Heart Revolution I | Know the Potential Uses and Limitations of the Mitral Clip |
|
| 09:40:00 |
ACS & AMI Management | Do We Need Prasugrel or Ticagrelor Beyond 30 Days? |
David J. Cohen
|
| 09:40:00 |
Valve & Structural Heart Revolution I | Percutaneous Approach to Mitral Valve Repair: Mitral Valve Replacement Technology Update |
Howard C. Herrmann
|
| 09:50:00 |
Valve & Structural Heart Revolution I | Direct Annuloplasty with Mitralign: Device Evolution, Technique and Clinical Trial Update |
|
| 09:50:00 |
ACS & AMI Management | PAR-1 Inhibitors: What Will Be the Role of Vorapaxar for the Treatment of ACS? |
David J. Moliterno
|
| 10:00:00 |
Break |
|
| 10:00:00 |
Valve & Structural Heart Revolution I | Panel Discussion: Is Percutaneous Valve Repair Ready for Prime Time? For Whom? |
Peter C. Block, Steven F. Bolling, Steven A. Goldstein, Howard C. Herrmann, Saibal Kar, Michael J. Mack, Renu Virmani, Ted Feldman, Thierry Georges Mesana
|
| 10:00:00 |
ACS & AMI Management | Panel Discussion: Selection and Duration of Antiplatelet Therapy for Patients with ACS and AMI in 2013 |
David J. Cohen, C. Michael Gibson, Neal Kleiman, Ron Waksman, Stephen Wiviott, Steven R. Steinhubl
|
| 10:05:00 |
CTO Forum | CTO COLLEGE: GETTING STARTED |
Craig A. Thompson, Gerald S. Werner
|
| 10:10:00 |
CTO Forum | Guiding Catheter Support Augmentation: Balloon Anchoring Techniques and Guidelines |
William L. Lombardi
|
| 10:15:00 |
Valve & Structural Heart Revolution I | Break |
|
| 10:15:00 |
ACS & AMI Management | Break |
|
| 10:20:00 |
CTO Forum | Anatomy of Contemporary CTO Guidewires and Selection Criteria |
Patrick Whitlow
|
| 10:25:00 |
Valve & Structural Heart Revolution I | MORE MITRAL VALVE INTERVENTIONS |
Peter C. Block, Balram Bhargava
|
| 10:25:00 |
ACS & AMI Management | ANTIPLATELET RESPONSIVENESS, GENETICS GENOMICS AND DRUG TO DRUG INTERACTIONS |
Neal Kleiman, Paul A. Gurbel
|
| 10:30:00 |
CTO Forum | Trends in Initial Guidewire Selection: For Antegrade and Retrograde Approach |
J. Aaron Grantham
|
| 10:30:00 |
Valve & Structural Heart Revolution I | Percutaneous Mitral Valve Complications and Bailout |
Peter C. Block
|
| 10:30:00 |
ACS & AMI Management | Does the Present Data Support Routine Platelet Responsiveness Testing? |
George Dangas
|
| 10:40:00 |
CTO Forum | Fundamentals of Wire Control and Evolution of the CTO Crossing Concept in Antegrade |
Gerald S. Werner
|
| 10:40:00 |
Valve & Structural Heart Revolution I | Dynamic Mitral Valve Ring Annuloplasty: The MiCardia Concept Clinical Update |
Maurice Buchbinder
|
| 10:40:00 |
ACS & AMI Management | Fibrinogen: Better Predictor of Ischemic Risk Than Platelet Reactivity? |
Ehtisham Mahmud
|
| 10:50:00 |
ACS & AMI Management | The Diabetic Patient and the Optimal Antiplatelet Therapy |
Dominick J. Angiolillo
|
| 10:50:00 |
Valve & Structural Heart Revolution I | Percutaneous Mitral Repair in High Surgical Risk Patients |
|
| 11:00:00 |
ACS & AMI Management | Genotyping: Which One Should We Perform, How to Interpret the Data and Is It Ready for Clinical Practice? |
Alan R Shuldiner
|
| 11:00:00 |
CTO Forum | Trends in Guidewire Selection in Refractory Cases |
Craig A. Thompson
|
| 11:00:00 |
Valve & Structural Heart Revolution I | Panel Discussion: What Should Be the Optimal Approach for Mitral Valve Repair - Minimally Invasive or Median Sternotomy Percutaneous Approach? |
Peter C. Block, Hans R. Figulla
|
| 11:05:00 |
ACS & AMI Management | DEBATE: TAILORING ANITPLATELET THERAPY |
|
| 11:10:00 |
ACS & AMI Management | We Should Tailor Antiplatelet Therapy Based on Platelet Function Testing and Genotyping |
Paul A. Gurbel
|
| 11:10:00 |
CTO Forum | Planning the Retrograde Attack: When to Switch to Retrograde-Predictors of Success vs. Failure |
William L. Lombardi
|
| 11:15:00 |
Valve & Structural Heart Revolution I | Clinical Experience with Percutaneous Mitral Repair |
Peter C. Block
|
| 11:20:00 |
CTO Forum | Selection of Collateral Channel |
|
| 11:20:00 |
ACS & AMI Management | There Is No Role for Platelet Function and Genomic Testing with the New Antiplatelet Agents |
Neal Kleiman
|
| 11:25:00 |
Valve & Structural Heart Revolution I | Transcatheter Approaches to Prosthetic Mitral Valve Failure and Paravalvular Leaks: Tips and Tricks |
|
| 11:30:00 |
Valve & Structural Heart Revolution I | MITRAL STENOSIS: FROM ASSESSMENT TO TREATMENT |
|
| 11:30:00 |
CTO Forum | Contrast Awareness: Strategies to Prevent Contrast Nephropathy |
Roxana Mehran
|
| 11:30:00 |
ACS & AMI Management | Panel Discussion: TBA |
|
| 11:35:00 |
Valve & Structural Heart Revolution I | Echocardiography of Mitral Stenosis: Severity and Important Echo Features |
Steven A Goldstein
|
| 11:40:00 |
ACS & AMI Management | THE ORAL FACTOR Xa INHIBITOR CONTROVERSY |
C. Michael Gibson, Manesh R. Patel
|
| 11:40:00 |
CTO Forum | Case Presentation III |
Gerald S. Werner
|
| 11:40:00 |
Valve & Structural Heart Revolution I | Timing of Intervention in Mitral Stenosis |
Ted Feldman
|
| 11:45:00 |
ACS & AMI Management | Did the Results of the RELY Trial Translate to Clinical Practice? |
C. Michael Gibson
|
| 11:50:00 |
Valve & Structural Heart Revolution I | How to Perform Balloon Mitral Valvuloplasty |
Augusto D. Pichard
|
| 11:55:00 |
ACS & AMI Management | Rivaroxaban in Patients with ST-Elevation Myocardial Infarction: Results from ATLAS ACS 2-TIMI 51 |
Manesh R. Patel
|
| 11:55:00 |
Valve & Structural Heart Revolution I | New Surgical Aspects of MVR |
Thierry Georges Mesana
|
| 11:55:00 |
CTO Forum | Case Presentation IV |
Jacques J. Koolen
|
| 12:05:00 |
ACS & AMI Management | How to Combine Antiplatelet Therapy with Oral Factor Xa Inhibitor |
Dominick J. Angiolillo
|
| 12:10:00 |
CTO Forum | Lunch and Visit the Exhibits and Simulators |
|
| 12:10:00 |
Valve & Structural Heart Revolution I | Lunch and Visit the Exhibits and Simulators |
|
| 12:15:00 |
ACS & AMI Management | Lessons from the ARISTOTLE Trial |
C. Michael Gibson
|
| 12:25:00 |
ACS & AMI Management | RUBY-1: What Is in the Future for Oral Factor Xa Inhibition in ACS? |
Sanjit S. Jolly
|
| 12:35:00 |
ACS & AMI Management | Panel Discussion: How to Choose Your Oral Factor Xa Inhibitor |
Dominick J. Angiolillo, C. Michael Gibson, Neal Kleiman, Manesh R. Patel, David J. Moliterno, Sanjit S. Jolly
|
| 12:50:00 |
ACS & AMI Management | Lunch and Visit the Exhibits and Simulators |
|
| 12:55:00 |
Valve & Structural Heart Revolution I | AORTIC STENOSIS |
Augusto D. Pichard, Michael J Reardon
|
| 13:00:00 |
Valve & Structural Heart Revolution I | The Pathological Insight from Explanted Percutaneous Heart Valves: What Do You Need to Know Before TAVR? |
Renu Virmani
|
| 13:05:00 |
CTO Forum | CTO MASTERS: TAKING ALL COMERS |
Barry D. Rutherford, Jacques J. Koolen
|
| 13:10:00 |
Valve & Structural Heart Revolution I | Dynamics in Patient Selection from Inoperable to Moderate Risk: TAVR vs. SAVR |
Alec Vahanian
|
| 13:10:00 |
CTO Forum | Guidewire Externalization |
J. Aaron Grantham
|
| 13:20:00 |
CTO Forum | LAST (Limited Antegrade Subintimal Tracking): From Knuckle Wires to BridgePoint |
Craig A. Thompson
|
| 13:20:00 |
Valve & Structural Heart Revolution I | TAVR or Surgery for Low Flow AS: Insights From the PARTNER Trial |
Howard C. Herrmann
|
| 13:30:00 |
CTO Forum | The Radial Approach for CTO PCI: Utility in the Retrograde and the Antegrade Approaches |
Shigeru Saito
|
| 13:30:00 |
Valve & Structural Heart Revolution I | How TVAR Impacts Cardiac Surgery and What the Credentials for the Surgeon Should Be |
|
| 13:35:00 |
ACS & AMI Management | ACUTE MI MANAGEMENT |
Eric R. Bates, Alice K. Jacobs, Jonathan S. Reiner, Lowell F. Satler
|
| 13:40:00 |
CTO Forum | Case Presentation: Retorgrade Approach |
Jacques J. Koolen
|
| 13:40:00 |
Valve & Structural Heart Revolution I | The Heart Valve Team: The US Experience |
Michael J Reardon
|
| 13:40:00 |
ACS & AMI Management | How to Minimize Bleeding in STEMI Patients |
Steven V. Manoukian
|
| 13:50:00 |
ACS & AMI Management | Medical Therapy for STEMI Patients During Interhospital Transport: Fibrinolytic and/or Anticoagulant? |
Eric R. Bates
|
| 13:50:00 |
Valve & Structural Heart Revolution I | Are We Ready to Perform TAVR in Intermediate Risk Patients? |
|
| 14:00:00 |
ACS & AMI Management | Transradial Access for ACS, Primary PCI and Anticoagulation Considerations |
Daniel H. Steinberg
|
| 14:00:00 |
Valve & Structural Heart Revolution I | Panel Discussion: Who Should Be a Candidate for TAVR in 2013? |
Howard C. Herrmann, Michael J Reardon, Alec Vahanian, Renu Virmani
|
| 14:00:00 |
CTO Forum | Trends in CTO PCI in Europe: Update from the Euro CTO Club |
Gerald S. Werner
|
| 14:05:00 |
Valve & Structural Heart Revolution I | TRANSCATHETER AORTIC VALVE REPLACEMENT SHOW ME THE DATA |
E. Murat Tuzcu, Alec Vahanian
|
| 14:10:00 |
Valve & Structural Heart Revolution I | New Data from PARTNER |
E. Murat Tuzcu
|
| 14:10:00 |
ACS & AMI Management | New Insights into the Mortality Benefit of Bivalirudin |
Gregg W. Stone
|
| 14:10:00 |
CTO Forum | Evolution of Strategy for the CTO PCI in the United States and Canada: An Update on Hybrid CTO PCI |
Richard R. Heuser
|
| 14:20:00 |
Valve & Structural Heart Revolution I | New Data from the French Registry |
Alec Vahanian
|
| 14:20:00 |
ACS & AMI Management | Primary PCI Update from NCDR and the Action Registry |
Manesh R. Patel
|
| 14:30:00 |
Valve & Structural Heart Revolution I | Bern-Rotterdam-Munich Propensity Analysis: SVR vs. TAVR in >4000 Patients |
Lutz Buellesfeld
|
| 14:30:00 |
ACS & AMI Management | STEMI Systems of Care - Update on Mission: We Are Better, Are the Patients as Well? |
Alice K. Jacobs
|
| 14:40:00 |
Valve & Structural Heart Revolution I | What Does the Future Hold for the Transapical Approach? |
Michael J. Mack
|
| 14:40:00 |
CTO Forum | Complications of CTO PCI III: Complications Unique to the Retrograde Approach |
|
| 14:40:00 |
ACS & AMI Management | Integrating the EMS with Hospital Primary PCI Programs: Update on the Washington DC Experience |
Jonathan S. Reiner
|
| 14:50:00 |
ACS & AMI Management | Door-In, Door-Out: Why the Delay? |
|
| 14:50:00 |
CTO Forum | Break |
|
| 14:50:00 |
Valve & Structural Heart Revolution I | Review of the Latest OUS Data from the CoreValve Studies |
|
| 15:00:00 |
ACS & AMI Management | Telemedicine to Expedite Patients’ Transfer: The Cell Phone Experience |
Lowell F. Satler
|
| 15:00:00 |
Valve & Structural Heart Revolution I | Review of the Transaortic and Subclavian Approaches |
Michael J Reardon
|
| 15:00:00 |
CTO Forum | INNOVATION: WHAT'S NEXT? |
Richard R. Heuser, Gerald S. Werner
|
| 15:05:00 |
CTO Forum | Newer Methods to Facilitate the Retrograde Approach |
Barry D. Rutherford
|
| 15:10:00 |
Valve & Structural Heart Revolution I | The TAVR Valve-in-Valve Technique: Fundamentals and Clinical Results |
|
| 15:10:00 |
ACS & AMI Management | Telemedicine to Analyze ST Segment to Detect Events Post MI |
C. Michael Gibson
|
| 15:15:00 |
CTO Forum | The Value of Multislice CT and Co-Registration for Planning and Guidance of CTO-PCI |
|
| 15:20:00 |
Valve & Structural Heart Revolution I | Break |
|
| 15:20:00 |
ACS & AMI Management | Panel Discussion: How Should We Optimize Door-to-Balloon Time for STEMI in 2013? |
Alice K. Jacobs, Manesh R. Patel, Jonathan S. Reiner, Lowell F. Satler, Gregg W. Stone, C. Michael Gibson
|
| 15:25:00 |
CTO Forum | Applications for Intravascular Ultrasound in Chronic Total Occlusions |
Barry D. Rutherford
|
| 15:30:00 |
Valve & Structural Heart Revolution I | UTILIZING IMAGING TECHNIQUES TO OPTIMIZE TAVI RESULTS |
Jeffrey J. Popma, Ron Waksman
|
| 15:35:00 |
CTO Forum | OCT Guidance for CTO Avinger |
Richard R. Heuser
|
| 15:35:00 |
ACS & AMI Management | Break |
|
| 15:35:00 |
Valve & Structural Heart Revolution I | Optimal Techniques to Determine Valve Annulus Size |
Raoul Bonan
|
| 15:45:00 |
Valve & Structural Heart Revolution I | Best Techniques for Valve Positioning and Deployment |
|
| 15:45:00 |
ACS & AMI Management | THROMBUS MANAGEMENT IN THE CATH LAB |
Steven V. Manoukian
|
| 15:50:00 |
ACS & AMI Management | INFUSE AMI: Lessons from a Mid-Sized Randomized Study |
Gregg W. Stone
|
| 15:55:00 |
CTO Forum | Most Advanced Subintimal and Re-Entry Technique Using BridgePoint Devices: Lessons from Complex Cases |
William L. Lombardi
|
| 15:55:00 |
Valve & Structural Heart Revolution I | Imaging and Quantification of Aortic Regurgitation after TAVI |
Lutz Buellesfeld
|
| 16:00:00 |
ACS & AMI Management | Thrombus Management in the Cath Lab: What are the Options and Outcomes? |
Sanjit S. Jolly
|
| 16:05:00 |
Valve & Structural Heart Revolution I | Echo Monitoring: Complications During Transcatheter Intervention for Structural Heart Disease |
Zuyue Wang
|
| 16:05:00 |
CTO Forum | Adjuvant Medical Therapy for Incomplete Revascularization |
Giora Weisz
|
| 16:05:00 |
ACS & AMI Management | MYOCARDIAL PRESERVATION AND RESTORATION |
Steven V. Manoukian
|
| 16:10:00 |
ACS & AMI Management | Translational Research for Myocardial Regeneration |
|
| 16:15:00 |
Valve & Structural Heart Revolution I | Is Transesophageal Echo During TAVR Essential? |
Alec Vahanian
|
| 16:15:00 |
CTO Forum | Tips and Tricks for Difficult Scenarios: Long CTO, Heavily Calcified, LM Bifurcation |
Gerald S. Werner
|
| 16:20:00 |
ACS & AMI Management | Use of FFR/OCT in ACS & AMI |
Giulio Guagliumi
|
| 16:25:00 |
Valve & Structural Heart Revolution I | Taped Case Demonstration: The Balloon- Expanding Transcatheter Valve System |
E. Murat Tuzcu
|
| 16:25:00 |
CTO Forum | Live Case Demonstration from Kusatsu Heart Center, Kusatsu, Japan |
|
| 16:30:00 |
ACS & AMI Management | How to Optimize Therapeutic Hypothermia and What to Expect |
Michael R. Mooney
|
| 16:40:00 |
ACS & AMI Management | The Use of Impella for Cardiogenic Shock Patients: Does it Save Lives? |
|
| 16:45:00 |
Valve & Structural Heart Revolution I | Taped Case Demonstration: The Self- Expanding Transcatheter Valve System |
|
| 16:50:00 |
ACS & AMI Management | IABP-SHOCK II: Randomized Comparison of Intra-Aortic Balloon Counterpulsation vs. Optimal Medical Therapy in Addition to Early Revascularization in Acute Myocardial Infarction Complicated by Cardiogenic Shock |
Manesh R. Patel
|
| 17:00:00 |
ACS & AMI Management | Adjourn |
|
| 17:05:00 |
Valve & Structural Heart Revolution I | Panel Discussion: What Imaging Is Required During TAVR? |
Raoul Bonan, E. Murat Tuzcu, Alec Vahanian, Zuyue Wang, Lutz Buellesfeld
|
| 17:20:00 |
Valve & Structural Heart Revolution I | Adjourn |
|
| 17:35:00 |
CTO Forum | Adjourn |
J. Aaron Grantham
|
| 18:25:00 |
Valve & Structural Heart Revolution I | VALVE & STRUCTURAL HEART REVOLUTION FOR THE SURGEON BREAKFAST I |
Steven F. Bolling, Niv Ad
|
| Monday, February 25, 2013 |
| 06:25:00 |
Complex Coronary Interventions I | BASIC RADIAL ACCESS |
Ramon Quesada
|
| 06:30:00 |
Complex Coronary Interventions I | Breakfast |
|
| 06:45:00 |
Complex Coronary Interventions I | Getting Radial Access LT and RT |
Saibal Kar
|
| 07:00:00 |
Complex Coronary Interventions I | Catheter Selection for Coronary Angiography |
|
| 07:10:00 |
Complex Coronary Interventions I | How to Become a Superb Radialist |
Sunil V. Rao
|
| 07:20:00 |
Complex Coronary Interventions I | Anticoagulant Choices in Transradial PCI in ACS |
Daniel H. Steinberg
|
| 07:35:00 |
Complex Coronary Interventions I | Hemostasis & Radial Artery Occlusion |
Ramon Quesada
|
| 07:45:00 |
Complex Coronary Interventions I | Case Reviews |
Shigeru Saito
|
| 12:15:00 |
Complex Coronary Interventions I | LUNCHEON SYMPOSIUM: CHANGING THE LANDSCAPE OF INTERVENTION IN THE US |
Jeffrey J. Popma, Ron Waksman
|
| 12:20:00 |
Complex Coronary Interventions I | Lunch |
|
| 12:45:00 |
Complex Coronary Interventions I | Does Second Generation DES Require A Shorter Duration of DAPT? |
Laura Mauri
|
| 12:55:00 |
Complex Coronary Interventions I | Expanding TAVR Beyond High Risk and Inoperable Patients |
Jeffrey J. Popma
|
| 13:05:00 |
Complex Coronary Interventions I | Renal Denervation Beyond Treatment of Hypertension |
Felix Mahfoud
|
| 13:15:00 |
Complex Coronary Interventions I | Drug Coated Balloons for Peripheral Artery Disease |
MICHAEL R. JAFF
|
| 13:25:00 |
Complex Coronary Interventions I | Panel Discussion |
David E. Kandzari, Jeffrey J. Popma, Ron Waksman, MICHAEL R. JAFF, Felix Mahfoud
|
| 13:55:00 |
Complex Coronary Interventions I | THE iMPACT TRIALS: SESSION I |
Maurice Buchbinder, Ron Waksman, William Fearon, Ian T. Meredith
|
| 14:00:00 |
Complex Coronary Interventions I | iMPACT Trial I |
|
| 14:10:00 |
Complex Coronary Interventions I | iMPACT Trial II |
|
| 14:20:00 |
Complex Coronary Interventions I | Commentary on the iMPACT Trials Session I |
Laura Mauri
|
| 14:30:00 |
Complex Coronary Interventions I | Live Case Demonstration from MedStar Washington Hospital Center, Washington, DC |
Kenneth M. Kent, Augusto D. Pichard, Lowell F. Satler
|
| 15:15:00 |
Complex Coronary Interventions I | Keynote Lecture: The Five Best Trials from 2012 that May iMPACT My Practice |
Gregg W. Stone
|
| 15:25:00 |
Complex Coronary Interventions I | Keynote Lecture What Does the Future Hold for Appropriateness, Guidelines, Reimbursement and Credentialing? |
David R. Holmes
|
| 15:35:00 |
Complex Coronary Interventions I | FFR, IVUS and OCT: Which Should We Use and When? |
Gary S. Mintz
|
| 15:45:00 |
Complex Coronary Interventions I | Lessons from FAME II and Review of the Results |
William Fearon
|
| 15:55:00 |
Complex Coronary Interventions I | Medical Therapy Should Work Well for Patients with Documented Ischemia |
William E. Boden
|
| 16:05:00 |
Complex Coronary Interventions I | The Future Is Medical Therapy: The Pipeline Is Robust |
Steven E Nissen
|
| 16:15:00 |
Complex Coronary Interventions I | Panel Discussion: How the COURAGE, FAME II and ISCHEMIA Trials Will Change Our Practice |
Gary S. Mintz, Steven E Nissen, William E Boden, William Fearon
|
| 16:30:00 |
Complex Coronary Interventions I | Live Case Demonstration from MedStar Washington Hospital Center, Washington, DC |
|
| 17:15:00 |
Complex Coronary Interventions I | Adjourn |
|
| Tuesday, February 26, 2013 |
| 06:25:00 |
Complex Coronary Interventions II | ADVANCED RADIAL ACCESS |
Ramon Quesada
|
| 06:30:00 |
Complex Coronary Interventions II | Breakfast |
|
| 06:45:00 |
Complex Coronary Interventions II | Transradial Peripheral Intervention |
|
| 06:55:00 |
Complex Coronary Interventions II | Transradial Primary PCI |
Daniel H. Steinberg
|
| 07:05:00 |
Complex Coronary Interventions II | Transradial in Women |
Sunil V. Rao
|
| 07:25:00 |
Complex Coronary Interventions II | Treating CTO via Radial? |
Richard R. Heuser
|
| 07:35:00 |
Complex Coronary Interventions II | The Economics of Transradial Access |
|
| 07:45:00 |
Complex Coronary Interventions II | Case Reviews |
Ramon Quesada
|
| 07:55:00 |
Complex Coronary Interventions II | COMPLEX CORONARY INTERVENTIONS |
Spencer B. King III, Ron Waksman
|
| 08:00:00 |
Complex Coronary Interventions II | Live Case Demonstration from MedStar Washington Hospital Center, Washington, DC |
Kenneth M. Kent, Augusto D. Pichard, Lowell F. Satler
|
| 08:30:00 |
Complex Coronary Interventions II | After FREEDOM and SYNTAX: Can PCI Be an Alternative to Surgery in Patients with Multivessel Disease? |
Spencer B. King
|
| 08:45:00 |
Complex Coronary Interventions II | Live Case Demonstration from Brussels University Hospital Brussels, Belgium |
Danny Schoors, Jacques J. Koolen
|
| 09:30:00 |
Complex Coronary Interventions II | How to Select Your DES: The Data-Driven Clinician’s View |
David A. Cox
|
| 09:40:00 |
Complex Coronary Interventions II | Optimal Duration of DAPT: Did We Go Too Far? |
Laura Mauri
|
| 09:45:00 |
Complex Coronary Interventions II | COMPLEX CORONARY INTERVENTIONS: COMPLEX LESION SUBSETS |
Jeffrey W. Moses
|
| 09:50:00 |
Complex Coronary Interventions II | Keynote Lecture: Unprotected Left Main: Pearls of Wisdom for Success |
Jeffrey W. Moses
|
| 10:00:00 |
Complex Coronary Interventions II | Bifurcation Management Update: Choosing the Right Strategy and Technique |
|
| 10:10:00 |
Complex Coronary Interventions II | ISAR-LEFT MAIN 2: A Prospective, Randomized Trial of Everolimus-Eluting vs. Zotarolimus-Eluting Stents in Patients with Unprotected Left Main Disease |
Adnan Kastrati
|
| 10:20:00 |
Complex Coronary Interventions II | Panel Discussion: Is there Enough Data to Support Routine PCI for Unprotected Left Main |
Adnan Kastrati, Jeffrey W. Moses
|
| 10:25:00 |
Complex Coronary Interventions II | BRAZIL @ CRT |
Alexandre Abizaid, Jeffrey W. Moses
|
| 10:30:00 |
Complex Coronary Interventions II | Live Case Demonstration from Morristown Medical Center, Morristown, NJ |
Maurice Buchbinder, Curtiss T. Stinis
|
| 11:30:00 |
Complex Coronary Interventions II | Late-Breaking Clinical Trials and Technology from South America |
Alexandre Abizaid
|
| 11:40:00 |
Complex Coronary Interventions II | Review of Structural Heart Programs in Brazil |
|
| 11:50:00 |
Complex Coronary Interventions II | How to Perform Successful PCI in SVG Lesions |
John S. Douglas
|
| 11:55:00 |
Complex Coronary Interventions II | IMPACT TRIALS – SESSION II |
Michael J. Cowley, Adnan Kastrati
|
| 12:00:00 |
Complex Coronary Interventions II | iMPACT Trial III |
|
| 12:10:00 |
Complex Coronary Interventions II | iMPACT Trial IV |
|
| 12:20:00 |
Complex Coronary Interventions II | Commentary on iMPACT Trials: Session II |
Adnan Kastrati
|
| 12:30:00 |
Complex Coronary Interventions II | Lunch and Visit the Exhibits and Simulators |
|
| 14:00:00 |
Complex Coronary Interventions II | Live Case Demonstration from Mount Sinai Medical Center, New York, NY |
Samin K. Sharma
|
| 14:55:00 |
Complex Coronary Interventions II | PROCEDURES TO iMPACT YOUR PRACTICE |
David A. Cox, Augusto D. Pichard
|
| 15:00:00 |
Complex Coronary Interventions II | How to Perform a Safe Transseptal |
Augusto D. Pichard
|
| 15:10:00 |
Complex Coronary Interventions II | Essentials for CTO Recanalization |
Richard R. Heuser
|
| 15:20:00 |
Complex Coronary Interventions II | How to Convert Your Access to the Radial Approach |
Ramon Quesada
|
| 15:30:00 |
Complex Coronary Interventions II | Alcohol Septal Ablations |
Kenneth M. Kent
|
| 15:40:00 |
Complex Coronary Interventions II | Thrombus Management and No Reflow in the Cath Lab: Tools and Tips |
|
| 15:50:00 |
Complex Coronary Interventions II | Cath Lab Nightmare: How to Avoid the Worst Complication |
John S. Douglas
|
| 16:00:00 |
Complex Coronary Interventions II | How to Handle a Complex Bifurcation Lesion |
Curtiss T. Stinis
|
| 16:10:00 |
Complex Coronary Interventions II | A Critical Evaluation of Bifurcation Trials & the State of our Knowledge |
|
| 16:15:00 |
Complex Coronary Interventions II | INTERESTING CASE PRESENTATIONS |
Rajiv Gulati, Jay Giri
|
| 16:20:00 |
Complex Coronary Interventions II | Interesting Case Presentation |
|
| 16:30:00 |
Complex Coronary Interventions II | Interesting Case Presentation |
|
| 16:40:00 |
Complex Coronary Interventions II | Interesting Case Presentation |
|
| 16:50:00 |
Complex Coronary Interventions II | CRT 2013 Closing Remarks |
Augusto D. Pichard
|
| 17:00:00 |
Complex Coronary Interventions II | Adjourn |
|
How We Rank